Search our Database of Scientific Publications and Authors

I’m looking for a

    933 results match your criteria Clinical Colorectal Cancer[Journal]

    1 OF 19

    Update on Hereditary Colorectal Cancer: Improving the Clinical Utility of Multigene Panel Testing.
    Clin Colorectal Cancer 2018 Jan 11. Epub 2018 Jan 11.
    Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia; Genetic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, Victoria, Australia; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia. Electronic address:
    Colorectal cancer (CRC), one of the most common cancers, is a major public health issue globally, especially in Westernized countries. Up to 35% of CRCs are thought to be due to heritable factors, but currently only 5% to 10% of CRCs are attributable to high-risk mutations in known CRC susceptibility genes, predominantly the mismatch repair genes (Lynch syndrome) and adenomatous polyposis coli gene (APC; familial adenomatous polyposis). In this era of precision medicine, high-risk mutation carriers, when identified, can be offered various risk management options that prevent cancers and improve survival, including risk-reducing medication, screening for early detection, and surgery. Read More

    Frequency of Surveillance and Impact of Surveillance Colonoscopies in Patients With Ulcerative Colitis Who Developed Colorectal Cancer.
    Clin Colorectal Cancer 2018 Jan 11. Epub 2018 Jan 11.
    Section of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA; Section of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address:
    Background: The risk of developing colorectal cancer (CRC) in patients with chronic ulcerative colitis (UC) is increased. The aim of this study was to evaluate if patients who developed CRC in the setting of UC were undergoing guideline-recommended surveillance colonoscopies and to determine the impact of surveillance on the staging of CRC.

    Patients And Methods: Data was obtained from the Veterans Affairs healthcare system to identify patients with UC and CRC. Read More

    Hormone Replacement Therapy and Colorectal Cancer Incidence and Mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Clin Colorectal Cancer 2018 Jan 12. Epub 2018 Jan 12.
    Department of Surgery, New York-Presbyterian Hospital/Weill Cornell Medicine, New York, NY; Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY.
    Introduction: Hormone replacement therapy has been shown to reduce colorectal cancer incidence, but its effect on colorectal cancer mortality is controversial. The objective of this study was to determine the effect of hormone replacement therapy on survival from colorectal cancer.

    Patients And Methods: We performed a secondary analysis of data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a large multicenter randomized trial run from 1993 to 2001, with follow-up data recently becoming mature. Read More

    Cardiorespiratory Fitness and Body Composition Responses to Different Intensities and Frequencies of Exercise Training in Colorectal Cancer Survivors.
    Clin Colorectal Cancer 2018 Jan 11. Epub 2018 Jan 11.
    School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, QLD, Australia.
    Introduction: Deteriorations in cardiorespiratory fitness (V˙o) and body composition are associated with poor prognosis after colorectal cancer treatment. However, the optimal intensity and frequency of aerobic exercise training to improve these outcomes in colorectal cancer survivors is unknown.

    Patients And Methods: This trial compared 8 weeks of moderate-intensity continuous exercise (MICE; 50 minutes; 70% peak heart rate [HR]; 24 sessions), with high-intensity interval exercise (HIIE; 4 × 4 minutes; 85%-95% HR) at an equivalent (HIIE; 24 sessions) and tapered frequency (HIIE-T; 16 sessions) on V˙oand on lean and fat mass, measured at baseline, 4, 8, and 12 weeks. Read More

    LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood Markers for Colorectal Cancer-Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result.
    Clin Colorectal Cancer 2017 Dec 12. Epub 2017 Dec 12.
    Department of Experimental, Diagnostic and Specialty Medicine, Unit of Histology, Embryology and Applied Biology, University of Bologna, Bologna, Italy. Electronic address:
    Background: A noninvasive blood test for the early detection of colorectal cancer (CRC) is highly required. We evaluated a panel of 4 mRNAs as putative markers of CRC.

    Materials And Methods: We tested LGALS4, CEACAM6, TSPAN8, and COL1A2, referred to as the CELTiC panel, using quantitative reverse transcription polymerase chain reaction, on subjects with positive fecal immunochemical test (FIT) results and undergoing colonoscopy. Read More

    A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer.
    Clin Colorectal Cancer 2017 Dec 15. Epub 2017 Dec 15.
    Digestive Oncology Unit, Department of Gastroenterology, Universitair Ziekenhuis Leuven, Leuven, Belgium.
    Background: The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untreated, unresectable advanced or metastatic colorectal cancer (CRC).

    Patients And Methods: Patients received oxaliplatin followed by irinotecan as intravenous infusions on day 1, with oral capecitabine taken twice daily (BID) on days 2 to 15 of a 3-week cycle. The dose ranges were explored as follows: oxaliplatin, 75 to 120 mg/m; irinotecan, 160 to 230 mg/m; capecitabine, 750 to 1000 mg/mBID. Read More

    Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer.
    Clin Colorectal Cancer 2017 Dec 13. Epub 2017 Dec 13.
    Department of Clinical Medicine, Indiana University Melvin Bren Simon Cancer Center, Indianapolis, IN. Electronic address:

    Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review.
    Clin Colorectal Cancer 2017 Dec 12. Epub 2017 Dec 12.
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medicine, New York, NY. Electronic address:
    Within gastrointestinal malignancies, primary hepatocellular carcinoma and pancreatic ductal adenocarcinoma (PDAC) are frequently associated with visceral thromboses (VT). Thrombus formation in the portal (PVT), mesenteric (MVT), or splenic vein (SVT) system leads to portal hypertension and intestinal ischemia. VT in PDAC may convey a risk of increased distal thrombosis and poses therapeutic uncertainty regarding the role of anticoagulation. Read More

    Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study.
    Clin Colorectal Cancer 2017 Dec 13. Epub 2017 Dec 13.
    Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China. Electronic address:
    Background: For most colorectal cancer patients with initial lung metastasis (LM), the only suitable treatments are palliative, including palliative local therapy and pharmacotherapy. We investigated the role of palliative local treatments in prolonging survival and the efficacy of different pharmacotherapies.

    Patients And Methods: After performing a medical record review of 2233 patients with metastatic colorectal cancer, 684 were identified as having LM. Read More

    Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
    Clin Colorectal Cancer 2017 Nov 1. Epub 2017 Nov 1.
    Tokyo Medical and Dental University, Tokyo, Japan.
    Background: This trial was designed to verify the superiority of 6 months of postoperative adjuvant chemotherapy with SOX (S-1 with oxaliplatin) with UFT (tegafur and uracil) with LV (leucovorin) in terms of disease-free survival in patients with high-risk stage III colon cancer. We report the results of a planned safety analysis.

    Patients And Methods: Patients who underwent curative resection for high-risk stage III colon cancer (any T, N2, or positive nodes around the origin of the feeding arteries) were randomly assigned to receive either UFT/LV (300-600 mg/d UFT with 75 mg/d LV on days 1-28, every 35 days, for 5 cycles) or SOX (100 mg/mof oxaliplatin on day 1 with 80-120 mg/d S-1 on days 1-14, every 21 days, for 8 cycles). Read More

    Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma.
    Clin Colorectal Cancer 2017 Nov 21. Epub 2017 Nov 21.
    Institute of Anatomy, University of Leipzig, Leipzig, Germany.
    Background: Nonresponse to chemotherapy in colorectal carcinoma (CRC) is still a clinical problem. For most established treatment regimens, no predictive biomarkers are available. Patient-derived tumor slice culture may be a promising ex vivo technology to assess the drug susceptibility in individual tumors. Read More

    Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.
    Clin Colorectal Cancer 2017 Oct 24. Epub 2017 Oct 24.
    Department of Oncology, Yale University, New Haven, CT.
    Background: Neoadjuvant chemoradiation (NCRT) is standard treatment for locally advanced rectal cancer. Pathologic complete response (pCR) has associated with improved survival. In modern phase III trials of NCRT, pCR ranges from 10% to 20%. Read More

    Autophagy Inhibition in Pancreatic Adenocarcinoma.
    Clin Colorectal Cancer 2017 Oct 28. Epub 2017 Oct 28.
    Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address:
    Although some progress has been made in recent years with the development of more effective chemotherapy regimens, new treatment approaches are needed to improve outcomes for patients with pancreatic adenocarcinoma. The cellular process of autophagy, a cell survival mechanism that allows cancer cells to survive the hazardous conditions of the tumor microenvironment and treatment, has emerged as a viable target in pancreatic cancer. We review the mechanism of autophagy, its role in pancreatic carcinogenesis, the preclinical and clinical evidence supporting targeting autophagy in patients with pancreatic adenocarcinoma, and areas of future investigation that hold promise for improving this treatment approach. Read More

    Evidence Suggests Sphingosine 1-Phosphate Might Be Actively Generated, Degraded, and Transported to Extracellular Spaces With Increased S1Pand S1PExpression in Colon Cancer.
    Clin Colorectal Cancer 2017 Nov 21. Epub 2017 Nov 21.
    Department of Clinical Laboratory Medicine, The University of Tokyo, Tokyo, Japan; Japan Agency for Medical Research and Development, Core Research for Evolutional Science and Technology (AMED-CREST), Tokyo, Japan.
    Background: A pivotal role of sphingosine 1-phosphate (S1P) in cancer has been suggested based on the ceramide-S1P rheostat theory that the intracellular balance between prosurvival S1P and proapoptotic ceramide determines cell fate. Upregulation of S1P-generating sphingosine kinases (SKs) and downregulation of S1P-degrading S1P lyase (SPL) might increase intracellular S1P levels to exert a prosurvival effect in cancer in general, such as colon cancer. However, we recently observed a distinct S1P metabolism in hepatocellular carcinoma tissues that increased SPL mRNA levels with reduced S1P levels. Read More

    Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer.
    Clin Colorectal Cancer 2017 Nov 21. Epub 2017 Nov 21.
    Department of Oncology, University of Alberta, Edmonton, AB, Canada.
    Background: Recent evidence from clinical trials suggests that primary tumor location in patients with metastatic colorectal cancer correlates with differential outcomes, and patients with tumors originating in the right side of the colon have inferior survival. We conducted a large population-based cohort study using individual patient data to confirm the prognostic importance of primary tumor location in the general population with metastatic colorectal cancer.

    Methods: A cohort of 1947 patients who were diagnosed with metastatic colorectal cancer from 1992 to 2010 was studied. Read More

    Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience.
    Clin Colorectal Cancer 2017 Nov 21. Epub 2017 Nov 21.
    Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN.
    Background: Leptomeningeal metastasis (LM) is an uncommon form of metastatic disease in many cancers. There remains a paucity of literature with regard to the course and management of LM in colorectal cancers (CRCs). The aim of this study was to estimate the incidence of LM in patients with CRC seen at our institution over a 15-year period, and to describe the clinical course and outcome of these cases. Read More

    Optimal Interval forF-FDG-PET After Chemoradiotherapy for Rectal Cancer.
    Clin Colorectal Cancer 2017 Nov 21. Epub 2017 Nov 21.
    Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
    Introduction: AlthoughF-fluorodeoxyglucose (FDG)-positron emission tomography (PET) has been increasingly used to evaluate the response to preoperative chemoradiotherapy (CRT) in patients with rectal cancer, the optimal intervals between completion of CRT, PET, and surgery have not been fully investigated.

    Patients And Methods: A total of 148 consecutive patients with rectal adenocarcinoma who received CRT followed by FDG-PET and radical surgery were retrospectively analyzed. The association between the FDG-PET maximum standardized uptake value (SUVmax) and pathological response was assessed using a logistic regression model, with a primary focus on the intervals between CRT and PET as well as between PET and surgery. Read More

    Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer.
    Clin Colorectal Cancer 2017 Nov 1. Epub 2017 Nov 1.
    Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. Electronic address:
    Background: Tissue biopsy is the gold standard for tumor genotyping, but it is an invasive procedure providing a single snapshot into tumor heterogeneity. Liquid biopsy approaches, encompassing the analysis of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), have been proposed as an alternative, with the potential of providing a comprehensive portrait of the tumor molecular landscape. In metastatic colorectal cancer (mCRC), both CTCs and ctDNA analysis have been investigated, but comparative analyses are limited. Read More

    A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
    Clin Colorectal Cancer 2017 Nov 21. Epub 2017 Nov 21.
    Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Canadian Centre for Applied Research in Cancer Control (ARCC), Toronto, Ontario, Canada. Electronic address:
    Background: Regorafenib and TAS-102 have shown to be superior to placebo in refractory metastatic colorectal cancer. However, no studies have directly compared both drugs. Giving the lack of standard options in this scenario, a systematic review to compare the efficacy and safety of regorafenib and TAS-102 was performed. Read More

    A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
    Clin Colorectal Cancer 2017 Oct 16. Epub 2017 Oct 16.
    Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
    Background: In some recently updated clinical guidelines, the fully humanized monoclonal antibody panitumumab, combined with irinotecan, has been recommended as an optional third-line chemotherapy for KRAS wild-type metastatic colorectal cancer (mCRC). The present prospective, multicenter phase II study evaluated the effectiveness and safety of short 15-minute panitumumab infusions.

    Patients And Methods: From January 2011 to December 2011, patients with KRAS wild-type mCRC were enrolled at 8 centers. Read More

    Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score.
    Clin Colorectal Cancer 2017 Oct 28. Epub 2017 Oct 28.
    Department of Medical Oncology, Biomedical Research Institute INCLIVA. CIBERONC, Hospital Clínico Universitario of Valencia, Valencia, Spain. Electronic address:
    Background: Adjuvant chemotherapy is controversial in patients with locally advanced rectal cancer after preoperative chemoradiation. Valentini et al developed 3 nomograms (VN) to predict outcomes in these patients. The neoadjuvant rectal score (NAR) was developed after VN to predict survival. Read More

    Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group.
    Clin Colorectal Cancer 2017 Nov 17. Epub 2017 Nov 17.
    Cancer Center Amsterdam, Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.
    Background: Clinical guidelines are generated to preserve high-quality evidence-based care. Data on the implementation of guidelines into clinical practice are scarce, despite that guideline adherence prevents over- and undertreatment and correlates with survival. Therefore, we investigated guideline adherence for the systemic treatment in high-risk stage II and stage III colon cancer and metastatic colorectal cancer. Read More

    Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?
    Clin Colorectal Cancer 2017 Oct 28. Epub 2017 Oct 28.
    CNRS, GICC UMR 7292, Université François-Rabelais de Tours, Tours, France. Electronic address:
    Colorectal cancer is a major problem for public health worldwide because of its frequency and its severity. Many efforts have been carried to target the vascular endothelial growth factor (VEGF) pathway, one of the main promoters of pathological angiogenesis. Therapeutic monoclonal antibodies against VEGF have emerged as essential biopharmaceuticals for the advanced stages of the disease, in association with appropriate backbone chemotherapy. Read More

    Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.
    Clin Colorectal Cancer 2017 Oct 23. Epub 2017 Oct 23.
    Division of Medical Oncology, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Cancer Control Research, Gastrointestinal Cancers Outcomes Unit Database, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Electronic address:
    Background: With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear.

    Patients And Methods: Using a population-based cohort of mCRC patients who received combination chemotherapy, we aimed to describe the use of IC/MC and their effect on overall survival (OS).

    Results: Among 617 patients, 120 (19%) had periods of IC, 67 (11%) had periods of MC, and 53 (9%) had periods of both. Read More

    Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis.
    Clin Colorectal Cancer 2017 Nov 15. Epub 2017 Nov 15.
    Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address:
    This study aimed to evaluate the influence of a waiting interval of ≥ 8 weeks between the end of preoperative neoadjuvant chemoradiotherapy (nCRT) and surgery on the outcomes of patients with locally advanced rectal cancer. We conducted a comprehensive literature review of retrospective and prospective studies from PubMed, Embase, and Cochrane Library databases to investigate the length of the preoperative nCRT-surgery waiting interval and outcomes in patients with locally advanced rectal cancer. The primary outcome measure was pathologic complete response (pCR) rate. Read More

    Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.
    Clin Colorectal Cancer 2017 Oct 16. Epub 2017 Oct 16.
    Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. Electronic address:
    Background: Somatic v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation, present in approximately 10% of metastatic colorectal cancer (mCRC) cases, is associated with poor prognosis. Patient outcome outside of clinical trials has only been reported in small series. We report real-world data on treatment and survival for BRAF-mutated (MT) patients at a single tertiary center, compared with a matched BRAF wild type (WT) control group. Read More

    Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study.
    Clin Colorectal Cancer 2017 Oct 19. Epub 2017 Oct 19.
    Service d'oncologie médicale, Hôpital Claude Huriez, University Hospital, Lille, France; Université Lille Nord de France, Lille, France.
    Background: We studied the relationship between intermediate criteria and overall survival (OS) in metastatic colorectal cancer (mCRC) patients who received first-line chemotherapy with bevacizumab.

    Patients And Methods: We assessed OS, progression-free survival (PFS), duration of disease control (DDC), the sum of the periods in which the disease did not progress, and the time to failure of strategy (TFS), which was defined as the entire period before the introduction of a second-line treatment. Linear correlation and regression models were used, and Prentice criteria were investigated. Read More

    Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.
    Clin Colorectal Cancer 2017 Oct 23. Epub 2017 Oct 23.
    Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address:
    Background: Molecular aberrations in KRAS, NRAS, BRAF, and PIK3CA have been well-described in advanced colorectal cancer. The incidences of other mutations are less known. We report results of molecular profiling of advanced colorectal cancer in an academic cancer center. Read More

    Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis.
    Clin Colorectal Cancer 2017 Oct 19. Epub 2017 Oct 19.
    Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
    Background: Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases remain largely unknown.

    Patients And Methods: We reviewed the data from metastatic CRC (mCRC) patients who had received oxaliplatin- or irinotecan-based systemic chemotherapy from 2005 to 2016. Read More

    Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer in Elderly Patients: Toxicity, Disease Control, and Survival Outcomes.
    Clin Colorectal Cancer 2017 Oct 16. Epub 2017 Oct 16.
    Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy; Spencer-Lorillard Foundation, Rome, Italy.
    Introduction: We report the treatment compliance, toxicity rates, and long-term clinical outcomes of elderly patients who received intensified neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC).

    Patients And Methods: We identified a retrospective cohort of patients aged ≥ 70 years with LARC who received intensified neoadjuvant CRT, followed by surgery and adjuvant chemotherapy, from 2007 to 2014. Intensified neoadjuvant CRT consisted of radiotherapy (total dose, 50. Read More

    Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Clin Colorectal Cancer 2017 Sep 28. Epub 2017 Sep 28.
    BresMed Health Solutions, Sheffield, UK; Department of Statistical Science, University College London, London, UK. Electronic address:
    Background: Treatment options at third-line and beyond for patients with late-line metastatic colorectal cancer (mCRC) are limited, and outcomes are poor with best supportive care (BSC). This study investigated the cost-effectiveness of trifluridine/tipiracil and regorafenib relative to BSC alone in patients with mCRC who have been previously treated with, or are not considered candidates for, standard chemotherapies.

    Materials And Methods: A partitioned survival model was constructed to assess the lifetime costs and benefits accrued by patients. Read More

    Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Clin Colorectal Cancer 2017 Sep 28. Epub 2017 Sep 28.
    Klinikum Oldenburg, Oldenburg, Germany.
    Background: Köhne prognostic score is used to classify patients with metastatic colorectal cancer (mCRC) as high, intermediate, or low risk. Using data from 2 phase III trials, we analyzed survival in patients categorized according to Köhne prognostic category and virus-induced rapidly accelerated fibrosarcoma murine sarcoma viral oncogene homolog B (BRAF) mutation.

    Patients And Methods: PRIME (Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy) (first-line) and 20050181 (second-line) were studies of chemotherapy with or without panitumumab. Read More

    Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes.
    Clin Colorectal Cancer 2017 Sep 28. Epub 2017 Sep 28.
    Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany; German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany. Electronic address:
    Background: Neoadjuvant therapy improves survival of patients with clinical stage II and III rectal cancer in clinical trials. In this study, we investigated the administration of neoadjuvant radiotherapy (neo-RT) and neoadjuvant chemoradiotherapy (neo-CRT) and its association with survival in resected patients in 2 European countries (The Netherlands and Sweden) and at 3 specialist centers.

    Materials And Methods: Administration of neoadjuvant treatment (all registries) and overall survival after surgery in The Netherlands and Sweden were assessed. Read More

    Clinical Features of Regorafenib-induced Liver Injury in Japanese Patients From Postmarketing Experience.
    Clin Colorectal Cancer 2017 Sep 28. Epub 2017 Sep 28.
    Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
    Background: Regorafenib (Stivarga) is an oral multikinase inhibitor currently approved for patients with metastatic colorectal cancer or gastrointestinal stromal tumor. Although hepatotoxicity has been a known product profile feature of regorafenib since its initial approval, its clinical features are limited to those found in the clinical trials.

    Patients And Methods: The present study was conducted in 2 analysis sets: a safety analysis set for metastatic colorectal cancer from solicited postmarketing surveillance (PMS) in Japan (n = 1227) and an analysis set for serious hepatic adverse drug reactions (n = 210) from all patients registered for regorafenib use. Read More

    Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study.
    Clin Colorectal Cancer 2017 Sep 28. Epub 2017 Sep 28.
    Department of Clinical Sciences, University of Barcelona and Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain.
    Background: Selecting elderly people with colorectal cancer (CRC) for adjuvant chemotherapy is challenging. Comprehensive geriatric assessment (CGA) can help by classifying them according to their frailty profile. The supposed benefit of chemotherapy is on the basis of the rate of treatment adherence. Read More


    Early-onset Colorectal Cancer is Distinct From Traditional Colorectal Cancer.
    Clin Colorectal Cancer 2017 Dec 23;16(4):293-299.e6. Epub 2017 Jun 23.
    Department of Medicine, Division of Hematology and Medical Oncology, Center for Advanced Digestive Care, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY. Electronic address:
    Background: Early-onset colorectal cancer (E-CRC) is increasing in incidence, unlike traditional CRC (T-CRC). We sought to characterize differences between E-CRC and T-CRC.

    Materials And Methods: Data sources included the Surveillance, Epidemiology, and End Results database, the Behavioral Risk Factor Surveillance Survey, and The Cancer Genome Atlas (TCGA). Read More

    Tumor Regression Grade After Neoadjuvant Chemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up.
    Clin Colorectal Cancer 2017 Aug 9. Epub 2017 Aug 9.
    Division of General and Hepatopancreatobiliary Surgery, Regina Elena National Cancer Institute, Rome, Italy. Electronic address:
    Background: The role of Mandard's tumor regression grade (TRG) classification is still controversial in defining the prognostic role of patients who have undergone neoadjuvant chemoradiation (CRT) and total mesorectal excision. The present study evaluated multiple correspondence analysis (MCA) as a tool to better cluster variables, including TRG, for a homogeneous prognosis.

    Patients And Methods: A total of 174 patients with a minimum follow-up period of 10 years were stratified into 2 groups: group A (TRG 1-3) and group B (TRG 4-5) using Mandard's classification. Read More

    Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management.
    Clin Colorectal Cancer 2017 Jun 27. Epub 2017 Jun 27.
    Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL. Electronic address:
    Colorectal carcinoma is the second leading cause of cancer-related deaths in the United States, with rectal cancer accounting for approximately one-third of newly diagnosed cases, thus representing a major socioeconomic health burden. Although minimally invasive procedures (ie, transanal excision) may be appropriate for a subset of patients with small, superficially invasive tumors, a more comprehensive trimodality approach with neoadjuvant chemoradiotherapy, total mesorectal excision, and systemic chemotherapy is recommended for medically operable patients with nonmetastatic, locally advanced rectal cancer (LARC). Although such multimodality therapy has markedly reduced local recurrence rates, there remains an estimated 5-year distant relapse rate of 35%, representing the leading cause of death in this population. Read More

    Clinical Analysis of Primary Colorectal Signet-Ring Cell Carcinoma.
    Clin Colorectal Cancer 2017 Jul 8. Epub 2017 Jul 8.
    Division of Colorectal Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
    The objective of the study was to investigate the clinicopathological features of primary colorectal signet-ring cell carcinoma. We retrospectively analyzed the clinical and survival data of 37 patients with primary colorectal signet-ring cell carcinoma. The mean survival time of patients in stage II, III, and IV were estimated using Student t test and the cumulative survival rates were estimated according to the method of Kaplan-Meier. Read More

    Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review.
    Clin Colorectal Cancer 2017 Jun 24. Epub 2017 Jun 24.
    Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
    Background: Decision-making regarding palliative treatment for patients with metastatic colorectal cancer (mCRC) is complex and comprises numerous decisions. Decision-making should be guided by the premise of maintaining and/or improving patients' quality of life, by patient preference, and by the trade-off between treatment benefits and harm. Decision support systems (DSSs) for clinicians (eg, nomograms) can assist in this process. Read More

    Intestinal and Extraintestinal Cancers Associated With Inflammatory Bowel Disease.
    Clin Colorectal Cancer 2017 Jun 27. Epub 2017 Jun 27.
    Division of Cancer Studies, King's College London, London, United Kingdom; Department of Histopathology, Guy's & St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address:
    Inflammatory bowel disease (IBD) with its 2 most common entities, ulcerative colitis and Crohn's disease, causes an increased risk of developing intestinal cancers. In fact, malignancies are the second most common cause of death after cardiovascular diseases in both sexes of patients with IBD. Risk factors for colorectal cancer in IBD correlate with the duration of the disease, extent of disease, the association with primary sclerosing cholangitis, family history, and early age at onset. Read More

    Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study.
    Clin Colorectal Cancer 2017 Jun 23. Epub 2017 Jun 23.
    Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada. Electronic address:
    Background: The utility of neoadjuvant radiotherapy (nRT) for the treatment of stage II and III rectal cancer is well-established. However, the optimal duration of nRT in this setting remains controversial. Using a population-based cohort of patients with stage II and III rectal cancer (RC) treated with curative intent, our aims were to (1) examine the patterns of nRT use and (2) explore the relationship between different nRT schedules and survival in the real-world setting. Read More

    Is Cure Possible After Sequential Resection of Hepatic and Pulmonary Metastases From Colorectal Cancer?
    Clin Colorectal Cancer 2017 Jun 23. Epub 2017 Jun 23.
    Centre Hépato-Biliaire, Assistance Publique Hôpitaux de Paris, Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France; Unité Mixte de Recherche S776, Institut National de la Santé et de la Recherche Médicale, Villejuif, France. Electronic address:
    Background: Surgical resection is an established therapeutic strategy for colorectal cancer (CRC) metastasis. However, controversies exist when CRC liver and lung metastases (CLLMs) are found concomitantly or when recurrence develops after either liver or lung resection. No predictive score model is available to risk stratify these patients in preparation for surgery, and cure has not yet been reported. Read More

    Effectiveness of Screening Modalities in Colorectal Cancer: A Network Meta-Analysis.
    Clin Colorectal Cancer 2017 Dec 4;16(4):252-263. Epub 2017 Apr 4.
    Basic Medical College, Lanzhou University, Lanzhou, Gansu, PR China. Electronic address:
    The aim of the study was to evaluate on the effectiveness of screening modalities in the prevention of colorectal cancer (CRC) occurrence and deaths. General meta-analysis was performed to produce pooled estimates of the effect of CRC incidence and mortality using a search of PubMed, Web of Science, and the Cochrane Library for eligible studies from January 1992 to March 2016. A network meta-analysis was performed to synthetically compare the effectiveness of 5 frequently used screening modalities. Read More

    Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial.
    Clin Colorectal Cancer 2017 Jun 17. Epub 2017 Jun 17.
    Department of Public Health Science, College of Medicine, Penn State College of Medicine, Hershey, PA.
    Background: Observational studies suggest that higher volumes of physical activity are associated with a lower risk of disease recurrence among survivors of colon cancer. However, the feasibility and safety of prescribing higher volumes of physical activity to survivors of colon cancer are unknown. Furthermore, the pathways through which exercise may reduce disease recurrence are unknown. Read More

    Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Clin Colorectal Cancer 2017 Dec 24;16(4):386-396.e1. Epub 2017 Mar 24.
    Genentech, Inc, South San Francisco, CA.
    Background: The present study examined real-world direct health care costs for metastatic colorectal cancer (mCRC) patients initiating first-line (1L) bevacizumab (BEV)- or cetuximab (CET)-containing regimen in 1L or 1L-through-second-line (1L-2L) therapy.

    Patients And Methods: Using a large US insurance claims database, patients with mCRC initiating 1L BEV- or 1L CET-containing regimen from January 1, 2008 to September 30, 2014 were identified. The per-patient per-month (PPPM) all-cause health care costs (2014 US dollars) were measured during 1L therapy and, for patients continuing to a 2L biologic-containing regimen, 1L-2L therapy. Read More

    Multidisciplinary Clinics for Colorectal Cancer Care Reduces Treatment Time.
    Clin Colorectal Cancer 2017 Dec 19;16(4):366-371. Epub 2017 Apr 19.
    Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address:
    Introduction: Management of locally advanced and metastatic colorectal cancer (CRC) requires the expertise of multiple specialists. Multidisciplinary clinics (MDCs) are a working model designed to facilitate delivery of coordinated care. The present study evaluated the effects of MDC on the time to treatment (TTT). Read More

    1 OF 19